HyQvia®

Understanding HyQvia®

HyQvia® is a subcutaneous immunoglobulin (SCIG) therapy used to treat Primary Immunodeficiency (PI) in adults and children aged 2 years and older. It provides antibody replacement therapy for individuals with weakened or absent immune responses, helping them better fight infections and maintain overall health. HyQvia® offers a convenient subcutaneous administration option, allowing for self-administration at home and improved quality of life for patients with PI.

How HyQvia® Works:

• Replaces missing immunoglobulins (IgG) to strengthen the immune system
• Provides long-term infection protection for PI patients
• Allows for at-home subcutaneous administration for added convenience

FDA Approval:

• HyQvia®: Approved on September 12, 2014, for adults with Primary Immunodeficiency (PI)

For more information, please visit the HyQvia® patient website and speak with your healthcare provider to determine if HyQvia® is the right treatment option for you.